AV Access for Hemodialysis: Cytograft has clinical trials ongoing in both Europe and South America. The autologous version of the graft has a commercialization permit and can be sold in Germany. Clinical results from Cytograft’s lead product, the Lifeline™ graft for hemodialysis access have been reported in both the New England Journal of Medicine and the Lancet.
Lower Limb Bypass for Critical Limb Ischemia: The Lifeline™ graft will soon be available to a select cohort of patients suffering from critical limb ischemia that have been targeted for amputation. The Lifeline™ graft, coupled with cell injections into the lower limb will be available for 'no option' patients in an attempt to delay or even avoid amputation. Patients with severe critical limb ischemia that are interested in enrolling in this study can email here for more information: CLI_clinicaltrials@cytograft.com.
Updates will be posted on this website and will also be available on www.clinicaltrials.gov.